drugset / Trial / NCT00624130

Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers

NCT00624130

Phase 3 Completed 453 enrolled Bayer
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to compare bleeding pattern of contraceptive Yasmin 20 to a marketed comparator.

Timeline

Start
2004-03
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desogestrel Small molecule 150 ug Oral
Subject Yasmin 20 Unknown 20 ug Oral
Subject drospirenone Unknown 3 mg Oral
Subject ethinyl estradiol Small molecule 20 ug Oral

Indications

No indication recorded.